Cargando…
Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma
Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells is under investigation as an approach to restore productive T cell immunosurveillance in patients with pancreatic ductal adenocarcinoma. Early findings demonstrate safety of this cell-based therapy and the capacity of CAR-...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063135/ https://www.ncbi.nlm.nih.gov/pubmed/25050204 http://dx.doi.org/10.4161/onci.28327 |
| _version_ | 1782321752478580736 |
|---|---|
| author | Beatty, Gregory L |
| author_facet | Beatty, Gregory L |
| author_sort | Beatty, Gregory L |
| collection | PubMed |
| description | Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells is under investigation as an approach to restore productive T cell immunosurveillance in patients with pancreatic ductal adenocarcinoma. Early findings demonstrate safety of this cell-based therapy and the capacity of CAR-expressing T cells to mediate anti-tumor activity as well as induce endogeneous antitumoral immune responses. |
| format | Online Article Text |
| id | pubmed-4063135 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | Landes Bioscience |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-40631352015-04-17 Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma Beatty, Gregory L Oncoimmunology Author's View Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells is under investigation as an approach to restore productive T cell immunosurveillance in patients with pancreatic ductal adenocarcinoma. Early findings demonstrate safety of this cell-based therapy and the capacity of CAR-expressing T cells to mediate anti-tumor activity as well as induce endogeneous antitumoral immune responses. Landes Bioscience 2014-04-17 /pmc/articles/PMC4063135/ /pubmed/25050204 http://dx.doi.org/10.4161/onci.28327 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
| spellingShingle | Author's View Beatty, Gregory L Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma |
| title | Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma |
| title_full | Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma |
| title_fullStr | Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma |
| title_full_unstemmed | Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma |
| title_short | Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma |
| title_sort | engineered chimeric antigen receptor-expressing t cells for the treatment of pancreatic ductal adenocarcinoma |
| topic | Author's View |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063135/ https://www.ncbi.nlm.nih.gov/pubmed/25050204 http://dx.doi.org/10.4161/onci.28327 |
| work_keys_str_mv | AT beattygregoryl engineeredchimericantigenreceptorexpressingtcellsforthetreatmentofpancreaticductaladenocarcinoma |